The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma

SIMPLE SUMMARY: In the last decade, proteasome inhibitors (PIs) have become a standard for the treatment of multiple myeloma (MM). As a consequence of the pleiotropic effects of PIs on various signaling pathways, synergistic or additive activities with other anti-myeloma therapies have been identifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Paradzik, Tina, Bandini, Cecilia, Mereu, Elisabetta, Labrador, Maria, Taiana, Elisa, Amodio, Nicola, Neri, Antonino, Piva, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000754/
https://www.ncbi.nlm.nih.gov/pubmed/33799793
http://dx.doi.org/10.3390/cancers13061235

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000754/
https://www.ncbi.nlm.nih.gov/pubmed/33799793
http://dx.doi.org/10.3390/cancers13061235

Ejemplares similares